Therapeutic Strategies With Selective CDK4/6 Inhibitors: An Oncologist’s Guide to Safe Inhibition of Uncontrolled Cellular Proliferation in Solid Tumors

Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer.

Richard Finn, MD Gary K. Schwartz, MD Geoffrey Shapiro, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: April 14, 2017 Expired: No longer available for credit

The first of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review critical data on the mechanisms of CDK4/6 inhibition and its clinical effects in various cancer types.

The second of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review critical studies on the clinical and preclinical characteristics of CDK4/6 inhibitors in multiple tumor types.

The third of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review key data on combining CDK4/6 inhibitors with hormone therapy, PI3K inhibitors, and others in multiple cancers.

In this downloadable slideset, Richard Finn, MD, Gary K. Schwartz, MD, and Geoffrey Shapiro, MD, PhD provide insight on the rationale for targeting cyclin dependent kinases 4 and 6 in cancer and highlight emerging clinical data with selective CDK4/6 inhibitors in multiple cancers.